Telomere dynamics in childhood leukemia and solid tumors: A follow-up study

Sonia Franco, M. F. Ozkaynak, C. Sandoval, O. Tugal, S. Jayabose, M. Engelhardt, M. A S Moore

Research output: Contribution to journalArticle

Abstract

Telomeres of hematopoietic cells shorten with age, possibly contributing to the aging-associated hematopoietic pathology (immunosenescence, malignant transformation). Accelerated telomere shortening is seen with replicative stress, such as during administration of serial chemotherapy cycles for the treatment of childhood cancer. To define the long-term consequences of pediatric cancer treatment on hematopoietic cell telomere length, we undertook a prospective 4-year follow-up study of a 61-patient cohort of pediatric malignancies in a community-based setting. We found that mononuclear cells (MNC) and granulocytes of children with standard-risk acute lymphoblastic leukemia (ALL) suffered minimal telomere shortening throughout therapy (less than 1 kbp; average follow-up, 20 months), while those of children with solid tumors showed greater and more heterogenous telomere attrition (0.5-2.8 kbp, average follow-up, 9 months). In addition, we evaluated the role of telomerase, the enzyme commonly up-regulated in pediatric leukemic and solid tumor cells for telomere length maintenance, as a disease marker. Serial determinations of telomerase in MNC were useful to confirm disease remission in leukemia, but play no role in the follow-up of children with solid tumors.

Original languageEnglish (US)
Pages (from-to)401-410
Number of pages10
JournalLeukemia
Volume17
Issue number2
DOIs
StatePublished - Feb 1 2003
Externally publishedYes

Fingerprint

Telomere
Leukemia
Telomere Shortening
Neoplasms
Telomerase
Pediatrics
Telomere Homeostasis
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Granulocytes
Therapeutics
Pathology
Drug Therapy
Enzymes

Keywords

  • Childhood cancer
  • Leukemia
  • Long-term follow-up
  • Pediatric solid tumors
  • Telomerase
  • Telomere

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Franco, S., Ozkaynak, M. F., Sandoval, C., Tugal, O., Jayabose, S., Engelhardt, M., & Moore, M. A. S. (2003). Telomere dynamics in childhood leukemia and solid tumors: A follow-up study. Leukemia, 17(2), 401-410. https://doi.org/10.1038/sj.leu.2402815

Telomere dynamics in childhood leukemia and solid tumors : A follow-up study. / Franco, Sonia; Ozkaynak, M. F.; Sandoval, C.; Tugal, O.; Jayabose, S.; Engelhardt, M.; Moore, M. A S.

In: Leukemia, Vol. 17, No. 2, 01.02.2003, p. 401-410.

Research output: Contribution to journalArticle

Franco, S, Ozkaynak, MF, Sandoval, C, Tugal, O, Jayabose, S, Engelhardt, M & Moore, MAS 2003, 'Telomere dynamics in childhood leukemia and solid tumors: A follow-up study', Leukemia, vol. 17, no. 2, pp. 401-410. https://doi.org/10.1038/sj.leu.2402815
Franco S, Ozkaynak MF, Sandoval C, Tugal O, Jayabose S, Engelhardt M et al. Telomere dynamics in childhood leukemia and solid tumors: A follow-up study. Leukemia. 2003 Feb 1;17(2):401-410. https://doi.org/10.1038/sj.leu.2402815
Franco, Sonia ; Ozkaynak, M. F. ; Sandoval, C. ; Tugal, O. ; Jayabose, S. ; Engelhardt, M. ; Moore, M. A S. / Telomere dynamics in childhood leukemia and solid tumors : A follow-up study. In: Leukemia. 2003 ; Vol. 17, No. 2. pp. 401-410.
@article{33526f33ff344aac923c32c26dbfba8c,
title = "Telomere dynamics in childhood leukemia and solid tumors: A follow-up study",
abstract = "Telomeres of hematopoietic cells shorten with age, possibly contributing to the aging-associated hematopoietic pathology (immunosenescence, malignant transformation). Accelerated telomere shortening is seen with replicative stress, such as during administration of serial chemotherapy cycles for the treatment of childhood cancer. To define the long-term consequences of pediatric cancer treatment on hematopoietic cell telomere length, we undertook a prospective 4-year follow-up study of a 61-patient cohort of pediatric malignancies in a community-based setting. We found that mononuclear cells (MNC) and granulocytes of children with standard-risk acute lymphoblastic leukemia (ALL) suffered minimal telomere shortening throughout therapy (less than 1 kbp; average follow-up, 20 months), while those of children with solid tumors showed greater and more heterogenous telomere attrition (0.5-2.8 kbp, average follow-up, 9 months). In addition, we evaluated the role of telomerase, the enzyme commonly up-regulated in pediatric leukemic and solid tumor cells for telomere length maintenance, as a disease marker. Serial determinations of telomerase in MNC were useful to confirm disease remission in leukemia, but play no role in the follow-up of children with solid tumors.",
keywords = "Childhood cancer, Leukemia, Long-term follow-up, Pediatric solid tumors, Telomerase, Telomere",
author = "Sonia Franco and Ozkaynak, {M. F.} and C. Sandoval and O. Tugal and S. Jayabose and M. Engelhardt and Moore, {M. A S}",
year = "2003",
month = "2",
day = "1",
doi = "10.1038/sj.leu.2402815",
language = "English (US)",
volume = "17",
pages = "401--410",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Telomere dynamics in childhood leukemia and solid tumors

T2 - A follow-up study

AU - Franco, Sonia

AU - Ozkaynak, M. F.

AU - Sandoval, C.

AU - Tugal, O.

AU - Jayabose, S.

AU - Engelhardt, M.

AU - Moore, M. A S

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Telomeres of hematopoietic cells shorten with age, possibly contributing to the aging-associated hematopoietic pathology (immunosenescence, malignant transformation). Accelerated telomere shortening is seen with replicative stress, such as during administration of serial chemotherapy cycles for the treatment of childhood cancer. To define the long-term consequences of pediatric cancer treatment on hematopoietic cell telomere length, we undertook a prospective 4-year follow-up study of a 61-patient cohort of pediatric malignancies in a community-based setting. We found that mononuclear cells (MNC) and granulocytes of children with standard-risk acute lymphoblastic leukemia (ALL) suffered minimal telomere shortening throughout therapy (less than 1 kbp; average follow-up, 20 months), while those of children with solid tumors showed greater and more heterogenous telomere attrition (0.5-2.8 kbp, average follow-up, 9 months). In addition, we evaluated the role of telomerase, the enzyme commonly up-regulated in pediatric leukemic and solid tumor cells for telomere length maintenance, as a disease marker. Serial determinations of telomerase in MNC were useful to confirm disease remission in leukemia, but play no role in the follow-up of children with solid tumors.

AB - Telomeres of hematopoietic cells shorten with age, possibly contributing to the aging-associated hematopoietic pathology (immunosenescence, malignant transformation). Accelerated telomere shortening is seen with replicative stress, such as during administration of serial chemotherapy cycles for the treatment of childhood cancer. To define the long-term consequences of pediatric cancer treatment on hematopoietic cell telomere length, we undertook a prospective 4-year follow-up study of a 61-patient cohort of pediatric malignancies in a community-based setting. We found that mononuclear cells (MNC) and granulocytes of children with standard-risk acute lymphoblastic leukemia (ALL) suffered minimal telomere shortening throughout therapy (less than 1 kbp; average follow-up, 20 months), while those of children with solid tumors showed greater and more heterogenous telomere attrition (0.5-2.8 kbp, average follow-up, 9 months). In addition, we evaluated the role of telomerase, the enzyme commonly up-regulated in pediatric leukemic and solid tumor cells for telomere length maintenance, as a disease marker. Serial determinations of telomerase in MNC were useful to confirm disease remission in leukemia, but play no role in the follow-up of children with solid tumors.

KW - Childhood cancer

KW - Leukemia

KW - Long-term follow-up

KW - Pediatric solid tumors

KW - Telomerase

KW - Telomere

UR - http://www.scopus.com/inward/record.url?scp=0037325715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037325715&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2402815

DO - 10.1038/sj.leu.2402815

M3 - Article

C2 - 12592340

AN - SCOPUS:0037325715

VL - 17

SP - 401

EP - 410

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 2

ER -